Session » Systemic Lupus Erythematosus – Animal Models - Poster II

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2787

Bortezomib Treatment Induces Higher Mortality Rate in Lupus Model Mice with High Disease Activity

9:00AM-11:00AM: Abstract Number: 2782

Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems

9:00AM-11:00AM: Abstract Number: 2783

Human Mesenchymal Stem Cells from Different Tissues Exert Distinct Therapeutic Effect on Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2781

Immunization with ApoB100 Peptide Vaccine Reduces Atherosclerosis Development in a Mouse Model of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2784

Mesenchymal Stem Cells Ameliorate Lupus By Promoting T Cell Apoptosis Via Bcl-2/Bim Independent Pathway in MRL/Lpr Mice

9:00AM-11:00AM: Abstract Number: 2789

Novel Glucocorticoid Prodrug Effectively Attenuates Late Stage Lupus Nephritis with Improved Safety Profile

9:00AM-11:00AM: Abstract Number: 2790

Selective Disruption of Estrogen Receptor Alpha Expression in Dendritic Cells of Lupus-Prone Mice Results in Increased Female-Specific Death

9:00AM-11:00AM: Abstract Number: 2788

Suppression of IL-1 Signaling Ameliorates Dermatitis in a Murine Model of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2791

Targeting Micro-RNAs Derived from Extracellular Vesicles to Inhibit of TLR7 and TLR8 Signaling Suppresses Inflammation in a Novel Human-Mouse Chimeric Model of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2786

The Janus Kinase Inhibitor Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

9:00AM-11:00AM: Abstract Number: 2785

Translatable in Vitro Immunocyte Functional Measures of CC-292 and CC-90008 Inhibitors of the Bruton’s Tyrosine Kinase (Btk)/Tec Family and the Pathology Observed in the MLR/Lpr Mouse Model of Systemic Lupus Erythematosus (SLE)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].